Association of miR-146a-5p and miR-21-5p with prognostic features in melanoma subtypes

Federico Venturi^{1,2,3}, Maria Naddeo¹, Martina Lambertini^{2,3}, Elisabetta Broseghini³, Milena Pariali⁴, Elena Campione⁵, Manuela Ferracin³, Emi Dika^{2,3}

¹Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy.
²Melanoma Centre, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia
³Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
⁴Center for applied Biomedical Research, S. Orsola-Malpighi University Hospital, Bologna, Italy
⁵Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

Objective

imi

To verify the association between the expression of miR-146a-5p and miR-21-5p and different melanoma features associated with patients' prognosis.

Methods

FFPE slices of 170 samples from patients with cutaneous melanoma were provided by Dermatopathology unit of Bologna University Hospital. RNA was isolated using miRNeasy kit and, after the extraction, RNA samples were converted to cDNA using miRCURY LNA RT kit. Starting from data obtained by CFX Manager software, the levels of miR-146a-5p and miR-21-5p were calculated. The association of miRNAs expression with selected histo-pathological features was considered significant for values of twosided P less or equal to 0.05. For all categorical variables, differences across the groups were analyzed using Mann-Whitney or unpaired t-test according to D'Agostino-Pearson Test for normality.

Results

MiR-146a-5p and miR-21-5p expression was significantly higher in all tumors with higher mitotic rate (≥1/mm2). Considering the ulceration status, we assessed that miR-146a-5p and miR-21-5p expression significantly higher was in ulcerated melanomas (Fig.1). We did not observe any difference in miRNAs expression when we considered all subtypes and their regression status (Fig.2). We then stratified miRNAs combined expression in melanoma different subtypes and surprisingly the MiR-146a-5p and miR-21-5p expression was was lower in lentigo maligna melanoma (LMM) than in all the other histotypes (OHT). Moreover, given the recognized association of miR-146a-5p and miR-21-5p with Breslow Thickness we also stratified (BT), the tumors according to both BT and tumor histotype and miR-146a-5p and miR-21-5p expression was lower even in LMM with BT ≥0.8 when compared to all the other histotypes with same BT (Fig.3).



Fig.1 Analysis of miR-146a-5p and miR-21-5pexpression in melanoma prognostic group:

(A), (B): Scatter plots showing a significant difference in miR-146a-5p (p=0.0383) and miR-21-5p (p=0.0004) expression in samples with mitotic rate ≥ 1/mm2 and < 1/mm2. (C) The plots show a higher miR-146aexpression and (D) а 5p significantly higher miR-21-5p (p=0.0031) expression in ulcerated samples compared to samples without presence of ulceration

Fig.2 Analysis of miR-146a-5p and miR-21-5p expression and regression status:

(A) and (B) miR-146a-5p and miR-21-5p did not shown different expression between samples with and presence absence of regression when both considering all subtypes. (C) No difference was found in miR-146a-5p expression in LMM subtype with or without regression (D), but a significant increased expression (p=0.0030) of miR-21-5p was observed in LMM subtype with presence of regression.



Fig.3 Differential miR-146a-5p and miR-21-5p expression in association with tumor histotypes (LMM vs OHT): (A), (B) Scatter plot graphs representation of miR-146a-5p and miR-21-5p relative expression in LMM vs OHT. A significantly difference in miRNA expression was found both for miR-146a-5p (p=0.0189) and miR-21-5p (p=0.0247) expression in the two groups. (C), (D) Scatter plots of miR-146a-5p and miR-21-5p relative expression LMM with BT \geq or < 0.8 mm (OBL \leq 0.8 mm). Significantly lower expression was observed both for miR-146a-5p (p=0.0331) and miR-21-5p (p=0.0473) in LMM with BT \geq 0.8 mm.

Corresponding author: Federico Venturi^{1,2,3} Contact: <u>federico.venturi@unifi.it</u> / +39 3386070215



P101